Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hemorrhagic transformation (HT) is a complication of severe ischemic stroke after revascularization. Patients with low platelet counts do not receive reperfusion therapies due to high risk of HT. The immunomodulatory drug fingolimod attenuated HT after tissue plasminogen activator in a thromboembolic stroke model, but the underlying mechanism is unknown. Fingolimod acts on several sphingosine-1-phosphate (S1P) receptors, prevents lymphocyte trafficking to inflamed tissues, and affects brain and vascular cells. This study aimed to investigate changes in S1P-signaling in response to brain ischemia/reperfusion and the effects of the S1P receptor modulator fingolimod on HT. We studied brain expression of S1P signaling components, S1P concentration, and immune cell infiltration after ischemia/reperfusion in mice. We administered fingolimod after ischemia to wild-type mice, lymphocyte-deficient Rag2 mice, and mice with low platelet counts. Ischemia increased S1P-generating enzyme SphK1 mRNA, S1P concentration, and S1P receptor-1 (S1P1) T-cells in the brain. Fingolimod prevented lymphocyte infiltration, and attenuated the severity of HT in Rag2 mice but it was ineffective under thrombocytopenia. Fingolimod prevented β-catenin degradation but not Evans blue extravasation. Ischemia/reperfusion upregulates brain S1P signaling pathway, and fingolimod exerts local effects that attenuate HT. Although fingolimod seems to act on the brain tissue, it did not prevent blood-brain barrier leakage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549179 | PMC |
| http://dx.doi.org/10.1038/s41598-019-44845-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.
J Neurol Neurosurg Psychiatry
September 2025
Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuroinflammation, Bron, France.
Unlabelled: BackgroundTarget trial emulation (TTE) offers a formal framework for causal inference using observational data, but its validity must be evaluated in each research domain by replicating randomised clinical trials (RCTs). We aimed to replicate eight RCTs evaluating the efficacy of disease-modifying therapies (DMTs) in multiple sclerosis (MS) using French registry data.
Methods: This multicentre, retrospective, observational study was conducted using data extracted in December 2023 from the (OFSEP) database.
Fingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network.
Stroke
September 2025
Department of Neurology, Yale University School of Medicine, New Haven, CT. (L.S.B.B., A.L.H., H.E.B., C.W.J., J.G., L.H.S.).
Background: Fingolimod is an immunomodulatory drug that has shown promising effects in stroke treatment, including improvements in neurofunctional recovery and a reduction in infarct size. Fingolimod modulates the sphingosine-1-phosphate receptors, which leads to the internalization of sphingosine-1-phosphate receptors on T and B lymphocytes, thereby preventing their egress from secondary lymphoid organs. Here, we report a secondary analysis from the Stroke Preclinical Assessment Network trial.
View Article and Find Full Text PDFRetrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis.
Ophthalmol Sci
July 2025
John F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Purpose: Sphingosine-1-phosphate (S1P) plays a pivotal role in cells as a bioactive lipid mediator, with emerging evidence suggesting that it may play a role in retinal ganglion cell survival, axonal growth, retinal pigment epithelium (RPE) barrier function, and photoreceptor function. While previous studies have documented associated ophthalmic effects such as fingolimod-associated macular edema, the specific impact of S1P receptor modulators on inner and outer retinal layer thicknesses requires further elucidation.
Design: Retrospective case series.
Severe infections in pediatric MS and related disorders patients on B-cell depleting therapies compared to sphingosine-1-receptor modulators.
Mult Scler Relat Disord
August 2025
Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Background: There is limited data on infection risk in pediatric onset multiple sclerosis and related disorders (MSARD).
Objectives: Analyze rate of severe infections in pediatric MSARD patients on B-cell depleting therapies (BCT) compared to fingolimod.
Methods: This was a retrospective chart review of pediatric MSARD patients from the Harvard Multiple Sclerosis Patient Database and the MGH Pediatric Multiple Sclerosis Center database treated with BCT or fingolimod.
Depression, Anxiety, and MSQOL-54 Outcomes in RRMS Patients Receiving Fingolimod or Cladribine: A Cross-Sectional Comparative Study.
Medicina (Kaunas)
August 2025
Department of Neurology, Faculty of Medicine, Dicle University, Diyarbakir 21090, Turkey.
: Multiple sclerosis (MS) is a chronic immune-mediated neurological disorder that primarily affects young adults and is frequently accompanied by psychiatric comorbidities such as depression and anxiety, both of which significantly diminish patients' quality of life (QoL). This study investigated the effect of two oral disease-modifying therapies (DMTs), fingolimod and cladribine, on mental health and QoL in patients with relapsing-remitting MS (RRMS). The aim of the study was to compare levels of depression, anxiety, and health-related quality of life (HRQoL) in RRMS patients treated with fingolimod or cladribine, and to evaluate their associations with clinical and radiological parameters.
View Article and Find Full Text PDF